18 Jul 2015
Technopath Clinical Diagnostics Enhances Product Offering
Tipperary, Ireland – 18th July 2015 - Technopath Clinical Diagnostics (the “Company”), a global leader in quality controls and software for clinical laboratories, today announced that it recently completed the acquisition from Canadian company, LAQC Systems Inc. of the technology and intellectual property underlying its existing IAMQC™ informatics platform for the clinical diagnostics laboratory market. The acquisition will allow the Company to fully control future development of this platform and enhance the product for customers.
Yuriy Kononyuk, CEO of LAQC Systems Inc. and the developer of the software platform will join the Company as Director of Informatics. Mr. Kononyuk brings significant experience in software development and the clinical diagnostics laboratory market to the Company.
Malcolm Bell, CEO of Technopath Clinical Diagnostics commented “This strategically important acquisition will allow Technopath Clinical Diagnostics to drive revenue growth by enhancing our product offering to customers and end users. Informatics will be a key driver of the global clinical diagnostics market and we are pleased to have Yuriy Kononyuk join our leadership team as Director of Informatics.”
The Company will now further develop the functionality of IAMQC for quality control applications for its customers and add new functionality for a wide range of data capture and analysis applications for the core clinical pathology laboratory of importance to both laboratories, reagent and equipment suppliers.
For further information please contact:
Peter Thornton, Chief Financial Officer
Technopath Clinical Diagnostics
Telephone: +353 61 335844
About Technopath Clinical Diagnostics
Technopath Clinical Diagnostics, a high growth privately held Irish life sciences company founded in 2004, is a global leader in the development and manufacture of quality controls and software which enhance the quality of patient testing by clinical laboratories. Technopath Clinical Diagnostics operates in the In Vitro Diagnostics (“IVD”) market – one of the fastest growing life science market segments. The Company launched its first products in 2008 and these are now sold globally in over 100 countries. In 2012, the Company signed a global supply agreement with Abbott and in 2013 achieved its first US product approval from the FDA.